128 related articles for article (PubMed ID: 35286894)
1. A pathway-guided strategy identifies a metabolic signature for prognosis prediction and precision therapy for hepatocellular carcinoma.
Shi Q; Liu Y; Lu M; Lei QY; Chen Z; Wang L; He X
Comput Biol Med; 2022 May; 144():105376. PubMed ID: 35286894
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of redox-immune based prognostic signature for hepatocellular carcinoma.
Tu K; Li J; Mo H; Xian Y; Xu Q; Xiao X
Int J Med Sci; 2021; 18(9):2030-2041. PubMed ID: 33850474
[TBL] [Abstract][Full Text] [Related]
3. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
Mo Z; Liu D; Rong D; Zhang S
Front Immunol; 2021; 12():611058. PubMed ID: 33679749
[No Abstract] [Full Text] [Related]
4. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-based classification and prognostic signature for clinical management of hepatocellular carcinoma.
Li K; Yang Y; Ma M; Lu S; Li J
World J Surg Oncol; 2023 Jul; 21(1):216. PubMed ID: 37481543
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic signaling pathway mediated by Notch pathway-related genes induces immunosuppression and immunotherapy resistance in hepatocellular carcinoma.
Ma P; Zou C; Xia S
Immunogenetics; 2022 Dec; 74(6):539-557. PubMed ID: 35895154
[TBL] [Abstract][Full Text] [Related]
7. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes.
Gu X; Guan J; Xu J; Zheng Q; Chen C; Yang Q; Huang C; Wang G; Zhou H; Chen Z; Zhu H
J Transl Med; 2021 Jan; 19(1):26. PubMed ID: 33407546
[TBL] [Abstract][Full Text] [Related]
8. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.
Yan Z; He M; He L; Wei L; Zhang Y
Front Immunol; 2021; 12():723271. PubMed ID: 34925311
[TBL] [Abstract][Full Text] [Related]
9. A novel hypoxia gene signature indicates prognosis and immune microenvironments characters in patients with hepatocellular carcinoma.
Zhang Q; Qiao L; Liao J; Liu Q; Liu P; Liu L
J Cell Mol Med; 2021 Apr; 25(8):3772-3784. PubMed ID: 33616276
[TBL] [Abstract][Full Text] [Related]
10. Characterization of immune features and immunotherapy response in subtypes of hepatocellular carcinoma based on mitophagy.
Wang Y; Peng B; Ning C; He S; Yang H; Mao Y; Sun L
Front Immunol; 2022; 13():966167. PubMed ID: 36304466
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of ADME genes as prognosis and therapy markers for hepatocellular carcinoma patients.
Wang J; Han K; Zhang C; Chen X; Li Y; Zhu L; Luo T
Biosci Rep; 2021 May; 41(5):. PubMed ID: 33988674
[TBL] [Abstract][Full Text] [Related]
12. Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature.
Zhao K; Xu L; Li F; Ao J; Jiang G; Shi R; Chen F; Luo Q
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32789471
[TBL] [Abstract][Full Text] [Related]
13. A Novel Hypoxic-Angiogenesis-Immune-Related Gene Model for Prognostic and Therapeutic Effect Prediction in Hepatocellular Carcinoma Patients.
Lv W; Yao Q
Dis Markers; 2022; 2022():9428660. PubMed ID: 35069936
[TBL] [Abstract][Full Text] [Related]
14. Promising key genes associated with tumor microenvironments and prognosis of hepatocellular carcinoma.
Pan L; Fang J; Chen MY; Zhai ST; Zhang B; Jiang ZY; Juengpanich S; Wang YF; Cai XJ
World J Gastroenterol; 2020 Feb; 26(8):789-803. PubMed ID: 32148377
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of metabolic pathway activity subtypes derived prognostic signature in hepatocellular carcinoma.
Huo J; Cai J; Wu L
Cancer Med; 2023 Jan; 12(1):898-912. PubMed ID: 35651292
[TBL] [Abstract][Full Text] [Related]
16. Identification of a four-gene metabolic signature predicting overall survival for hepatocellular carcinoma.
Liu GM; Xie WX; Zhang CY; Xu JW
J Cell Physiol; 2020 Feb; 235(2):1624-1636. PubMed ID: 31309563
[TBL] [Abstract][Full Text] [Related]
17. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
Jiang H; Ning G; Wang Y; Lv W
Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
[TBL] [Abstract][Full Text] [Related]
18. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
19. Construction and Validation of a Prognostic Gene-Based Model for Overall Survival Prediction in Hepatocellular Carcinoma Using an Integrated Statistical and Bioinformatic Approach.
Dessie EY; Tu SJ; Chiang HS; Tsai JJP; Chang YS; Chang JG; Ng KL
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562824
[TBL] [Abstract][Full Text] [Related]
20. Identification of a thirteen-gene signature predicting overall survival for hepatocellular carcinoma.
Zhou X; Liu C; Zeng H; Wu D; Liu L
Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33835133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
